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The activities of pathways that regulate malignant transformation can be
influenced by microRNAs (miRs). Recently, we showed that increased
expression of five tumour-suppressor miRs, miR-508-3p, miR-508-5p, miR-
509-3p, miR-509-5p and miR-130b-3p, correlate with improved clinical
outcomes in human ovarian cancer patients, and that miR-509-3p attenuates
invasion of ovarian cancer cell lines. Here, we investigate the mechanism
underlying this reduced invasive potential by assessing the impact of
these five miRs on the physical properties of cells. Human ovarian cancer
cells (HEYA8, OVCAR8) that are transfected with miR mimics representing
these five miRs exhibit decreased invasion through collagen matrices,
increased cell size and reduced deformability as measured by microfiltration
and microfluidic assays. To understand the molecular basis of altered
invasion and deformability induced by these miRs, we use predicted and
validated mRNA targets that encode structural and signalling proteins
that regulate cell mechanical properties. Combined with analysis of gene
transcripts by real-time PCR and image analysis of F-actin in single cells,
our results suggest that these tumour-suppressor miRs may alter cell phys-
ical properties by regulating the actin cytoskeleton. Our findings provide
biophysical insights into how tumour-suppressor miRs can regulate the
invasive behaviour of ovarian cancer cells, and identify potential therapeutic
targets that may be implicated in ovarian cancer progression.1. Introduction
High-grade serous ovarian cancer (HGSC) is the most lethal gynaecological
cancer in the USA [1]. Most patients initially respond to platinum and
taxane-based treatments, but subsequently develop chemoresistance; the 5-
year survival rate is only 44% [1]. The critical need for successful treatment
strategies motivated The Cancer Genome Atlas (TCGA) Network to catalogue
the genetic alterations in approximately 500 HGSC samples [2]. Through com-
putational analysis of TCGA data, we identified a panel of differentially
expressed microRNA (miR) mature strands (miR-508-3p, miR-508-5p,
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2miR-509-3p, miR-509-5p and miR-130b-3p), for which higher
levels of expression are associated with longer survival in
HGSC patients [3]. Improved survival can be associated
with reduced metastasis and decreased invasion of cancer
cells. Our previous work shows that overexpression of
tumour-suppressor miR-509-3p in human ovarian cancer cell
lines impedes invasion throughMatrigel matrices [3]. Further-
more, downregulation of miR-130b-3p is associated with
cancer progression and multidrug resistance in ovarian
cancer [4]. While miRs such as miR-509-3p impact prolifer-
ation and cell signalling behaviour [5,6], which could
influence metastatic dissemination and growth of cancer
cells, the invasion andmigration of cancer cells from a primary
tumour involves physical and mechanical processes. Detailed
biophysical investigations at the single-cell level could
thus deepen our understanding of how elevated levels of
tumour-suppressor miRs may result in clinical benefits.
During cancer progression, tumour cells undergo changes
in their physical properties, including their deformability and
adhesion, which can contribute to their altered motility and
invasive behaviour [7–9]. Such physical properties are
relevant for understanding how cells deform through
narrow gaps in the circulatory system, which is required for
metastasis [10]; they are also essential for invasion through
the extracellular matrix (ECM), connective tissue and endo-
thelial linings of blood or lymph vessels [11]. The ECM is
composed of glycoproteins, proteoglycans and fibrous pro-
teins such as collagens [12], which form a network with
gaps or pores that range in diameter from 10 nm to 5 mm
[13–15]; increased cell and nuclear volume is correlated
with reduced invasion of breast cancer cells through in vitro
collagen gels [16]. To overcome the physical constraints
imposed by ECM barriers, cells secrete proteases, such as
matrix metalloproteases (MMPs), which can increase the
size of gaps between neighbouring fibres [17–19]. Many
types of tumour cells are also more deformable compared
with benign cells [20–22], and cell mechanical properties
are associated with invasion efficiency [16,23,24]. Compared
with less deformable ovarian tumour cells that have a
higher Young’s modulus or decreased compliance, cancer
cells that are more deformable tend to move more quickly
through the gaps of in vitro transwell migration and invasion
assays [23,24]. Considering the large deformations required
during extra- and intravasation as well as invasion into sur-
rounding tissues, changes in the size and deformability of
single tumour cells could play a functional role in disease
progression. We hypothesize that altered cell physical proper-
ties may reduce cell invasion, and thereby contribute to the
improved prognosis, which is associated with higher levels
of tumour-suppressor miRs.
To determine the effect of tumour-suppressor miRs on
cancer cell physical properties, we overexpress a panel of
five miRs (miR-508-3p, miR-508-5p, miR-509-3p, miR-
509-5p and miR-130b-3p) in human ovarian carcinoma cells
(HEYA8, OVCAR8) using miR mimics for each. We character-
ize the ability of cells to invade through collagen matrices
in the presence of an MMP inhibitor; the inhibitor limits
matrix degradation and enhances the extent to which cells
must deform to move through the steric constraints of col-
lagen gels. To determine cell deformability, we drive cells
to passively deform through micrometre-scale pores using
microfluidic deformation [25,26] and parallel microfiltration
(PMF) [27] assays. To gain insight into the molecular basisof the effects of tumour-suppressor miRs on cell physical
properties, we identify predicted miR–mRNA targets that
encode structural or signalling proteins that regulate cell
mechanical properties; we also verify transcript levels of
selected predicted targets. Through analysis of miR–mRNA
interactions, our results show that these tumour-suppressor
miRs are predicted to target genes that are implicated in
the structure and remodelling of the actin cytoskeleton. By
imaging cells in both suspended and adhered states using
imaging flow cytometry and confocal microscopy, we
observe increased levels of filamentous actin (F-actin) with
miR overexpression, and a strong inverse correlation between
invasive potential and F-actin levels in adhered cells. Taken
together, our results reveal that these five tumour-suppressor
miRs that reduce cell invasive behaviour are implicated in the
structure and remodelling of the actin cytoskeleton. Our find-
ings also identify novel proteins for future study that may
potentially serve as new druggable targets that play a role
in ovarian cancer cell invasion and disease progression.2. Material and methods
2.1. Cell culture and transfection
Ovarian cancer cells (HEYA8, OVCAR8) are cultured in
RPMI 1640 medium supplemented with 10% heat-inactivated
fetal bovine serum (FBS) and 1% of penicillin/streptomycin.
Cells are grown under standard conditions at 378C and 5%
CO2. MiR mimics and scrambled (SCR) negative controls
are transiently transfected at 24 nM using Lipofectamine
2000 in serum-free OptiMEM medium, followed by the
addition of 10% FBS after 4 h in serum-free conditions. All
assays are performed 72 h post-transfection.
2.2. Scratch wound invasion assay
To measure cell invasive potential, cells are seeded on
30 mg ml21 collagen-coated 96-well microplates at a density
of 27 000 cells per well. After overnight culture at 378C with
5% CO2, scratch wounds are generated on the confluent cell
monolayer using sterile P1000 pipette tips and washed with
PBS to remove debris and to prevent dislodged cells from
settling and reattaching. We prepare collagen gels on ice
immediately prior to use by diluting collagen type I (rat tail
collagen I, Corning) in RPMI 1640 medium with 50 mM of
the MMP inhibitor GM6001 (Santa Cruz Biotechnology), to
a final concentration of 1 mg ml21 collagen; 0.1 M NaOH is
added to bring the pH to 7.4. Thereafter, 50ml of collagen
solution is added to each well and incubated at 378C for
1 h, followed by the addition of 200 ml of culture medium
with 50 mM GM6001. To confirm reduced MMP activity, we
measure total protease activity using 25 ml of 20 mM fluoro-
genic peptide substrate in 75 ml of conditioned media after
72 h of cell culture (ES010, R&D Systems), followed by a
30 min incubation. Levels of fluorescence associated with
hydrolysis of quenched fluorogenic peptide substrates are
measured at 320 nm excitation and 405 nm emission.
Images of the scratch wounded cells are acquired every 2 h
using an ORCA-R2 Digital CCD camera (C10600, Hama-
matsu) mounted on an automated Zeiss Axio Imager Z1
microscope equipped with a 5 objective (N-Achroplan
5/0.13, Zeiss) and temperature controlled environmental
rsob.royalsocietypublishing.org
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3chamber set to 378C. We analyse images using IMAGEJ soft-
ware to determine the percentage of wound closure, or
relative invasion, where w(t) is the area covered by cells at
time t:
% relative invasion ¼ 100 wðtÞ  wð0Þ
total image area wð0Þ :
2.3. Scanning electron microscopy imaging
Collagen gels are fixed in 2.5% glutaraldehyde solution
(0.1M sodium phosphate buffer, pH 7.2) for 2 h at room
temperature, followed by post-fixation in 1% osmium tetrox-
ide (0.1M sodium phosphate buffer, pH 7.2) for 1 h at room
temperature. Samples are then dehydrated using a graded
ethanol series (30%, 60%, 80%, 100% ethanol, for 10 min
each), critical-point dried (Tousimis), sputter-coated with
1–2 nm of gold (Denton) and imaged by scanning electron
microscopy (JEOL).
2.4. mRNA/miR isolation and quantitative polymerase
chain reaction
Relative gene expression levels are measured using the
Applied Biosystems 7300 Real-Time PCR System. Briefly,
total RNA is extracted from cells using the miRNeasy Mini
Kit (Qiagen) following the manufacturer’s protocol. RNA
purity and concentration are measured using an ND-100
Nanodrop spectrophotometer (Thermo Scientific). Total
RNA is reverse transcribed (High Capacity cDNA Reverse
Transcription Kit, Applied Biosystems) using 500 ng of
RNA for each 20 ml reaction. We perform real-time polymer-
ase chain reaction (qRT-PCR) using TaqMan Gene Expression
Assays (Applied Biosystems) in a final volume of 20 ml con-
taining 4 ng of template. Expression levels are normalized
to levels of 18S and calculated as fold change (22DDCT) with
respect to the scrambled negative control samples. To
obtain absolute quantification of miR levels, we use droplet
digital PCR (Bio-Rad). Purified RNA is polyadenylated
using poly-A polymerase (New England Biolabs) following
the manufacturer’s protocol and reverse transcribed using
the iScript Select cDNA Synthesis Kit (Bio-Rad). We measure
the number of miRs detected in 2 mg of RNA for samples
with low levels of miRs and 50 ng of total RNA for the
samples with miR overexpression. Each 20 ml reaction con-
taining 1 EvaGreenSupermix (Bio-Rad), 1 gene-specific
primers and 4 ml of cDNA is partitioned into droplets using
the QX200 droplet generator and then transferred to a 96-
well plate for PCR amplification using a thermal cycler.
After PCR, droplets are analysed on a QX200 droplet
reader to measure the target miR concentrations. We calculate
the average miR copy number per cell based on the quantity
of RNA extracted from approximately 105 cells from three
independent experiments.
2.5. Predicted miR targeting
To clarify the molecular basis of the mechanotype changes
observed with miR overexpression, we identify predicted
tumour-suppressor miR targets that are implicated in regulat-
ing the mechanical properties of cells, including genes that
encode for both structural and signalling proteins thatregulate cytoskeletal structure and dynamics. We score
genes as potential miR targets using three sets of binding
site predictions: TargetScan (v. 7.1) [27], miRmap (201301e)
[28] and miRanda-mirSVR [29]; for mirSVR, we use target
site predictions with ‘good’ scores for conserved miRs
(miR-130b-3p) and for non-conserved miRs (miR-508-5p,
miR-508-3p, miR-509-5p and miR-509-3p). We consider pre-
dicted targets that are in the top 50th percentile of scores
for each method. Because a 30-UTR can have more than one
predicted binding site for a mature strand of a given miR,
we use a percentile based on the sum of scores of all pre-
dicted sites for a mature strand on a 30-UTR. The total
percentile scores reflect the expected effect of a miR in redu-
cing a transcript’s abundance; reporting percentiles facilitates
comparing scores among methods.2.6. Parallel microfiltration
To measure the ability of cells to deform through micrometre-
scale pores, we use a PMF device [27] with polycarbonate
membrane filters of 10 mm pore size (Millipore). To minimize
cell–surface interactions, membranes and loading wells are
treated with 1% bovine serum albumin in deionized water
for 1 h at 378C. Transfected cells are trypsinized at 72 h
post-transfection, filtered through 35mm filters to mini-
mize cell clusters and resuspended to a final concentration
of 9  105 cells ml21 in culture medium prior to loading.
We determine the density of the cell suspension using an
automated cell counter (TC20, Bio-Rad); these measure-
ments also confirm that more than 88% of cells are single
cells (N ¼ 2) (electronic supplementary material, figure
S3a,b). To measure cell deformability using PMF, we apply a
uniform air pressure of 7 or 14 kPa for 45 s, collect the samples
retained in the top wells and calculate percentage retention ¼
(mf/mi)  100%, where mi is the mass of cell suspension
loaded and mf is the mass remaining in the top well after
filtration. Percentage retention depends on the driving
pressure, the cell size relative to the pore size and the intrinsic
cell mechanical properties [27–29].2.7. Microfluidic device fabrication and operation
For microfluidic deformation experiments, we use standard
soft lithography techniques to fabricate polydimethylsiloxane
(PDMS) (Sylgard 184 Silicone Elastomer, Dow Corning)
devices. To probe cell deformability, we use a device design
as previously described [25]. In brief, a master mould of the
device is patterned from photoresist onto a silicon wafer.
PDMS is moulded onto the wafer and cured at 658C for 4 h,
then removed, cleaned and covalently bonded to glass cover-
slips after exposure to oxygen plasma. To minimize surface
adhesion, we add 0.1% v/v F-127 surfactant (Invitrogen) to
cell suspensions. We use an applied pressure of 28 kPa to
drive cells in suspension through the device constrictions.
The resulting cell deformations are imaged using a high-
speed camera (PhantomMiro EX1, Vision Research) mounted
on an inverted light microscope (Zeiss) equipped with a 20
objective (20/0.40 Ph2 Corr, LD Achroplan, Zeiss). Images
are analysed using a custom algorithm in MATLAB (Math-
works) to extract cell size, which is determined before each
cell enters the constriction, and transit time; stiffer cells tend
to have longer transit times [26,29–31].
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Figure 1. Quantification of miR levels using droplet digital PCR. MiR copy number in negative control and miR-overexpressing samples 72 h after transfection with
tumour-suppressor miRs. Data are shown for (a) HEYA8 and (b) OVCAR8 cells. The average numbers of miR copies per cell are calculated based on the quantity of
RNA extracted from approximately 105 cells. Error bars show the standard deviation of N ¼ 2 independent experiments.
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42.8. Imaging cells and subcellular structures
To visualize F-actin and determine cell/nuclear size, we
image cells in suspension using the ImageStream multispec-
tral imaging flow cytometer (Amnis Corporation). Cells are
fixed in 4% paraformaldehyde and permeabilized with
0.2% Triton X-100. After blocking, cells are incubated with
Alexa Fluor 488-phalloidin (Thermo Scientific), followed by
DRAQ5 nuclear stain (Thermo Scientific). We measure
morphological features such as cell size, nuclear size and
cortical-to-intracellular F-actin levels using the ImageStream
Data Analysis and Exploration Software (IDEAS) (Amnis
Corporation). To assess the distribution of F-actin, we deter-
mine the ratio of cortical-to-intracellular F-actin levels,
where the cortical F-actin is measured by the average pixel
intensity within 0, 7 pixels (0 , 3.5 mm) from the boundary
of the cell, and intracellular F-actin is measured by the aver-
age pixel intensity within the internal region that is more than
3.5 mm from the boundary of the cell. Cell and nuclear sizes
are determined by measuring the projected area and extract-
ing the diameter assuming a perfect circle. To visualize
F-actin in adhered cells, cells are seeded on collagen-coated
glass slides, fixed with 4% paraformaldehyde and labelled
with Alexa Fluor 488-phalloidin. We perform confocal ima-
ging using a Zeiss laser scanning microscope (LSM 5
Exciter) equipped with a 63 objective (63/1.2 W Korr
UV-VIS-IR, C-APOCHROMAT, Zeiss), and argon ion
(488 nm) and helium-neon lasers (633 nm) for excitation.
We measure the total integrated fluorescence intensity of
F-actin for individual cells using IMAGEJ and determine the
fold-change fluorescence relative to the SCR treatment.3. Results and discussion
In our previous work, we showed that higher expression
levels of the tumour-suppressor miRs miR-508-3p, miR-508-
5p, miR-509-3p, miR-509-5p and miR-130b-3p in human
ovarian tumours correlate with improved patient prognosis
and can discriminate improved survival in HGSC patients
[3,32]. Here, to obtain fold-change increases in miR levels
that are similar to the increased levels between cancer
patients at early versus advanced stages of disease [33,34],
we transiently transfect miRs into HEYA8 and OVCAR8
ovarian cancer cells.3.1. Quantification of miR expression levels
To determine how the fold-change increase in tumour-
suppressor miRs with overexpression relates to clinical
contexts, we first measure endogenous levels of miRs in
HEYA8 and OVCAR8 cells using droplet digital PCR
(figure 1). Our analysis reveals that these tumour-suppressor
miRs have endogenously low copy numbers in the non-
treated cells. For example, in HEYA8 cells, miR-130b-3p is
present at approximately one copy per cell, while miR-508-3p,
miR-508-5p, miR-509-3p and miR-509-5p are even less abun-
dant, ranging from 1024 to 1023 copies per cell (figure 1a).
Overall, the OVCAR8 cells show similar endogenous levels of
miRs compared to the HEYA8 cells (figure 1b). Following tran-
sient transfection of these miRs, expression levels in HEYA8
increase by up to five orders of magnitude up to 20–120
copies per cell 72 h after transfection. The cells treated with
miR-508-3p show the largest fold increase of approximately
105, while levels of miR-130b-3p increase by approximately
102-fold. For OVCAR8, we observe up to an approximately
104 fold increase in miR levels, with 50–160 copies per cell
72 h after transfection. Across the panel of tumour-suppressor
miRs, we observe on average a 104-fold increase in miR levels.
These transient transfections generate changes in the levels of
tumour-suppressor miRs that are similar to those observed in
clinically relevant contexts. For example, miR-508-3p, miR-
509-3p and miR-509-5p are less abundant by approximately
10 to 103-fold in ovarian cancer patients with stage III versus
stage I disease [33], and miR-508-3p and miR-508-5p are
approximately 10–102-fold less abundant in metastatic serous
epithelial ovarian tumours than in primary tumours [34].3.2. MiR overexpression hinders cell invasion through
collagen matrices
To deform through gaps of the ECM, invading cells undergo
major changes in shape that are associated with cytoskeleton
remodelling. The magnitude of cell deformation required to
pass through narrow pores depends on the ECM network
mesh size and mechanical properties of the fibrous proteins.
To determine the extent to which elevated levels of miRs
hinder cell invasion through an ECM, we perform invasion
assays using a type I collagen matrix (figure 2a), which is the
most abundant structural component of the ovarian ECM
[35]. Scanning electron microscopy (SEM) of the 1 mg ml21
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Figure 2. Effect of miR overexpression on cell invasion through a collagen matrix. (a) Scratch wound assay where cells invade through a collagen gel. The upper
panel shows a top view of the scratch; the cells on right and left sides invade into this wounded region, which is overlaid with a collagen gel. Scale bar, 200 mm.
The bottom panel shows a scanning electron micrograph of the fibrous structure of a 1 mg ml21 collagen gel. Scale bar, 1 mm. (b,d ) Invasion time course for
HEYA8 (N ¼ 3) and OVCAR8 (N ¼ 3) cells in 1 mg ml– 1 collagen type I in the presence of a protease inhibitor, 50 mM GM6001. (c,e) Relative invasion of HEYA8
and OVCAR8 cells at 24 h for different miR treatments. One-way ANOVA with a Tukey post hoc test: ***p, 0.001, n.s., p. 0.05, compared to the scrambled
control treatment (SCR). All error bars show the standard error of the mean.
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5collagen gels that we use in our invasion assay reveals that the
average gap size is 0.5–2 mm; this is significantly smaller than
the 23–25mm median diameter of cells overexpressing the
tumour-suppressor miRs. Invading tumour cells can also
increase thematrix gap size by secretingproteases that degrade
collagen. Indeed, elevated levels of several MMPs, including
MMP-2 andMMP-9, in ovarian cancer cells are associated
with increased invasive potential, and with poor survival of
ovarian carcinoma patients [36–38]. To reduce the potential
role of matrix degradation and thereby enhance the require-
ment for cells to deform during invasion, we treat cells with
the broadband MMP inhibitor GM6001, which suppresses
the invasion of cells through type I collagen matrices [39]. We
confirm that GM6001 decreases protease activity in con-
ditioned medium taken from cell culture 24 h after treatment
with GM6001 (electronic supplementary material, figure S1).
Over the 24-h invasion time course, the HEYA8 mock and
SCR-treated control cells show progressive closure of the
scratch wound. We observe no significant differences between
mock and SCR-treated cells (94%, 83% relative invasion,
respectively, p ¼ 0.33). By the endpoint of 24 h, the wound is
nearly completely healed, with 83–94% wound closure
(figure 2b,c). By contrast, HEYA8 cells overexpressing miR-
508-3p, miR-509-3p and miR-130b-3p show a marked
reduction in wound closure (41%, 10%, 31% relative invasion,
respectively, p, 0.001). Cells with elevated levels of miR-509-
5p also show significantly reduced invasion compared to themock and SCR cells (63% relative invasion, p, 0.001). Across
ourmiR panel, we observe a significant decrease inwound clo-
sure rate with overexpression of all miRs except miR-508-5p.
Compared to the HEYA8 cells, OVCAR8 cells show reduced
invasion of the mock and SCR controls (34–36% relative inva-
sion, p, 0.001). The more rapid invasion of HEYA8 cells
compared to OVCAR8 cells is consistent with the mesenchy-
mal phenotype of the HEYA8 cells versus the epithelial-like
OVCAR8 cells; cells become more motile during epithelial-
to-mesenchymal transition (EMT) [40]. Only miR-509-3p
shows a significant decrease in wound closure and speed of
the wound front in both cell lines (electronic supplementary
material, figure S2; p, 0.001 in each cell line). The reduced
invasion of miR-509-3p-overexpressing cells through collagen
matrices is consistent with previous results showing decreased
invasion of ovarian cancer cells through Matrigel [3], as well
as reduced migration of human epithelial lung cancer and
renal cancer cells in scratch wound assays [5,6]. Our results
are also in agreement with other studies that show reduced
invasion with overexpression of miR-508-3p in gastric [41]
and renal [5] cancers, as well as with overexpression of
miR-130b-3p in pancreatic cancer [42].
3.3. Elevated levels of miRs alter cell physical properties
To determine the effect of elevated levels of tumour-
suppressor miRs on cell deformability, we perform a
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Figure 3. Cells that overexpress tumour-suppressor miRs have longer transit times through microfluidic constrictions. (a) We apply air pressure of 28 kPa to drive
cells through a PDMS microfluidic device with constrictions that have a width of 7 mm and height of 10 mm; the constriction diameter is approximately half the
median cell size of 23–25 mm. Cell deformations are imaged using a high-speed camera and analysed using a custom image processing algorithm to extract the
time for each cell to transit through the first constriction (C1). Micrographs show a representative HEYA8 cell that has a transit time of 42.9 ms. Scale bar, 10 mm.
(b) Density scatter plot showing relationship between cell size and transit time for N ¼ 889 individual SCR-treated HEYA8 cells. The shaded grey region indicates
cells with an apparent diameter of 13–15 mm; we apply this size filter to compare cells of similar sizes across the miR panel. An upstream filter minimizes larger
cells and cell aggregates from entering the constriction region. (c,d ) Distributions of transit times for HEYA8 and OVCAR8 cells treated with tumour-suppressor miRs.
Each panel displays the number of cells per sample, which are compiled over N ¼ 2 independent experiments. Horizontal lines denote medians, boxes represent the
25th and 75th percentiles and whiskers show the 10th and 90th percentiles. SCR, scrambled control. Mann–Whitney test: n.s., not significant; ***p, 0.001,
**p, 0.01, compared to the SCR treatment.
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6microfluidic deformation assay that enables us to measure
both the size and transit time of single cells as they deform
and pass through a micrometre-scale channel. In this assay,
the time for transit exhibits a strong dependence on cell
deformability, with cells that are more compliant having
shorter transit times than stiffer cells [28,30,31,43,44]. Transit
time also shows a weak dependence on cell size [30,45]; how-
ever, larger cells get filtered out in the upstream filter region
of the device and we further size filter the data to compare
the transit times for cells of similar sizes across our miR
panel (figure 3b). Both HEYA8 and OVCAR8 cells that over-
express miR-508-3p, miR-508-5p and miR-130b-3p have
significantly longer transit times compared with the mock
and SCR controls (figure 3c,d ). For miR-508-3p, we observe
the longest median transit time in HEYA8, and also an
increased median transit time for OVCAR8 compared to
SCR (approx. 8 longer median transit time for HEYA8,
2 for OVCAR8; p, 0.001). For the OVCAR8 cells, we find
an approximately 3 increased median transit time with
overexpression of miR-130b-3p compared to the SCR cells
( p, 0.001). We find a similar 2 increase in median transit
time for both cell lines with overexpression of miR-509-3p
compared to SCR control cells (OVCAR8, p ¼ 0.002;
HEYA8, p ¼ 0.06). Our results also show a 3 increased
median transit time with overexpression of miR-509-5p in
HEYA8 cells compared to SCR ( p, 0.001), but no significant
change for OVCAR8 cells ( p ¼ 0.87). Overall, our results
show that overexpression of tumour-suppressor miRs
results in an increase in transit time, indicating that cells
overexpressing these miRs are less deformable.
To confirm measurements of cell deformability using an
independent assay, we use PMF [27]. In PMF, a bulk suspen-
sion of cells is filtered through a membrane with 10 mm pores
in response to applied air pressure (figure 4a). We measure
the percentage retention by determining the fraction of
sample volume that is retained in the top loading well after
applying pressure for a defined period of time. Cells that
are less deformable are more likely to occlude the pores,
resulting in higher retention; a larger cell size could alsoincrease retention. Given the potential confounding effects
of cell size on filtration, we display our retention data
together with cell size distributions (figure 4b–e). We observe
that cells overexpressing different miRs exhibit similar cell
size distributions, with median sizes that are within +2 mm
(figure 4b–e; electronic supplementary material, table S1
and figure S5a); these results suggest that differences in
retention are not strongly influenced by cell size but instead
reflect differences in cell deformability among the different
miR treatments.
Transfected HEYA8 cells that overexpress tumour-
suppressor miRs consistently show a retention that is
approximately 30–40% higher than the mock and SCR
controls after 45 s of filtration through 10 mm pores at 7 kPa
( p, 0.001) (figure 4b). To resolve differences in retention
between cells with different miR treatments, we increase
the applied pressure. At a driving pressure of 14 kPa, we
observe that the mock and SCR control samples completely
filter through the membrane on the experimental timescale;
this is consistent with our PMF results at lower pressure,
where mock and SCR exhibit the lowest retention, indicating
these cells are the most deformable (figure 4c). HEYA8 cells
that overexpress tumour-suppressor miRs show higher reten-
tion at 14 kPa, reflecting that more of these cells occlude the
10 mm pores even at this higher driving pressure. Cells with
elevated levels of miR-508-3p and miR-509-3p show the high-
est retentions (92+ 5% and 83+ 5%, respectively) compared
to the other miR treatments (p, 0.001), while retention of
miR-508-5p (59+5%), miR-509-5p (39+ 5%) and miR-
130b-3p (56+ 5%) overexpressing cells is still significantly
higher than the control samples at this increased driving
pressure (figure 3c) (p, 0.001). By contrast, OVCAR8 cells
show higher levels of retention than HEYA8 at the same
pressures; this is consistent with the more invasive HEYA8
cells being more deformable. For OVCAR8 cells at 14 kPa
driving pressure, we observe higher retention for miR-
508-3p (82+11%), miR-509-5p (86+6%) and miR-130b-3p
(80+8%) compared to the mock and SCR ( p, 0.001), but
no significant change in retention for cells treated with
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7miR-508-5p ( p ¼ 0.9) and miR-509-3p ( p ¼ 0.9). Overall, we
find that miR-508-3p results in the largest increase in reten-
tion in both HEYA8 and OVCAR8 cells. Overexpression of
miR-509-5p and miR-130b-3p also results in consistently
higher retention relative to the SCR control in both cell types.
The results of these complementary filtration and micro-
fluidic methods to measure cell deformability are in good
agreement. Overexpression of miR-508-3p in both HEYA8
and OVCAR8 causes increased retention and transit time,
reflecting decreased cell deformability. While both methods
probe the ability of cells to transit through micrometre-scale
pores, we do not observe the same trends for all miRs; this
could reflect differences in the readouts for the bulk (PMF)
versus single cell (transit time) deformability assays (see the
electronic supplementary material for further discussion). For
example, overexpression of miR-509-3p in HEYA8 cells results
in a slight shift to increased transit times, but a statistically sig-
nificant increase in retention compared with SCR cells; this
could result from occlusion due to the longer transiting cells.
3.4. Prioritizing genes of the mechanome that are
implicated in cytoskeletal structure and dynamics
To determine the mechanisms through which the miRs in our
panel could be inducing changes in cell physical properties,and ultimately invasive behaviour, we determine predicted
targets of miRs that could be implicated in cell mechani-
cal properties. We prioritize genes that encode major
cytoskeletal proteins (such as vimentin), proteins that interact
with components of the cytoskeleton (actin cross-linkers like
filamin A), as well as proteins that regulate cytoskeletal
organization (NF-kB). We assess the probability of miR-
gene targeting that influences mRNA transcript levels using
three independent and favourably ranked [46] sets of binding
site predictions: TargetScan (v. 7.1) [27], miRmap (201301e)
[28] and miRanda-mirSVR [29]. To enable comparisons of
the predictions from each resource, we assess the binding
site scores as percentiles with values between 0 and 1, and
report only genes that are in the top 50th percentile of targets
for all three resources, or are validated targets (figure 5a).
Below, we summarize predicted and validated targeting
that is relevant for the effects of our tumour-suppressor
miRs on cell deformability.
3.4.1. miR-508-3p
NFKB1, which encodes the protein NF-kB, is a predicted
target of miR-508-3p (TargetScan ¼ 0.96, mirSVR ¼ 0.90,
miRmap ¼ 0.82). This miR is validated as inactivating
canonical NF-kB signalling in gastric cancer cell lines and
primary tumours [41,51,52]. NF-kB disrupts tissue
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Figure 5. Predicted effects of tumour-suppressor miRs on cytoskeletal structure and dynamics. (a) Network showing predicted and validated miR targets and
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miR–mRNA targets are determined using TargetScan v. 7.1, miRanda-mirSVR and miRmap; all targets displayed have scores in the top 50th percentile of predicted
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8organization and cellular morphology; it is a regulator
of genes involved in actin organization and cell adhesion
in breast cancer cells [53]. Another predicted target of
miR-508-3p is leupaxin (LPXN) (TargetScan ¼ 0.97,
mirSVR ¼ 0.73, miRmap ¼ 0.62), which is a member of the
paxillin family of focal adhesion proteins. Leupaxin directly
affects cytoskeletal organization and dynamics through
its interaction with the actin-binding protein caldesmon
(CALD1) [54,55].
3.4.2. miR-508-5p
ACTR2 is a highly scoring predicted target of miR-508-3p
(TargetScan ¼ 0.99, mirSVR ¼ 0.94, miRmap ¼ 0.89), which
encodes a major constituent of the ARP2/3 complex that is
essential for lamellipodial actin assembly and protrusion
formation, both of which are implicated in cell motility [56].
3.4.3. miR-509-3p
Predicted targets of this miR include YAP1 (TargetScan ¼
0.96, mirSVR ¼ 0.95, miRmap ¼ 0.97), which encodes the
Yes associated transcription factor Yap1 that is implicated
in regulation of tissue tension, as well as in cell shape and
migration [57]. The effects of Yap1 on the actin cytoskeleton
are regulated via the Rho GTPase, ARHGAP18, which sup-
presses F-actin polymerization by inhibiting RhoC [58] and
RhoA [50]. Recently, we validated YAP1 as a direct target
of miR-509-3p [3]. We also identify ARHGAP1, the Rho
GTPase-activating protein 1, as a potential target of
miR-509-3p (TargetScan ¼ 0.92, mirSVR ¼ 0.76, miRmap ¼
0.78); this protein also regulates assembly of F-actin [59].
While RAC1, which is a member of the Rho family of
GTPases, scores highly as a predicted target using only one
method (TargetScan ¼ 0.99), it is a validated target of miR-509-3p [6]. Rac1 contributes to the formation of membrane
protrusions and cell–matrix adhesions that are essential in
cell motility [60] and is also overexpressed in several types
of tumours [61–63].
3.4.4. miR-509-5p
The intermediate filament protein, vimentin (VIM), is a
highly scoring predicted target of miR-509-5p (TargetScan ¼
0.97, mirSVR ¼ 1.00, miRmap ¼ 0.95). Vimentin is widely
used as a biomarker for mesenchymal-type cells. This protein
is also observed to promote cell motility and increase focal
adhesion dynamics during epithelial-to-mesenchymal
transition [64]. Depletion of vimentin also results in reduced
cell stiffness [65–67]. MiR-508-5p is also predicted to target
RHOC (TargetScan ¼ 0.99, mirSVR ¼ 0.66, miRmap ¼ 0.77),
which encodes a Rho GTPase protein that plays an important
role in cell motility [48,49]. RhoC expression positively corre-
lates with cancer metastasis in melanoma and breast cancer
[49,68,69].
3.4.5. miR-130b-3p
The tumour-suppressor PTEN, encoding phosphatidyl-
inositol-3,4,5-trisphosphate 3-phosphatase, is a validated
target of miR-130b-3p [70] that is also highly scored as a
predicted target (TargetScan ¼ 0.94, mirSVR ¼ 0.87,
miRmap ¼ 0.95). Downregulation of PTEN promotes the
motility of fibroblasts through stimulation of Cdc42 and
Rac1 activity [70–72]. Another predicted target of miR-
130b-3p is DIAPH3 (TargetScan ¼ 0.67, mirSVR ¼ 0.81,
miRmap ¼ 0.93), which encodes diaphanous-related formin-
3 (Drf3). Drf3 binds to profilin (PFN1) [73,74] and guides
its downstream effector, Cdc42, to the cell cortex where it
plays a role in remodelling the actin cytoskeleton [75]. This
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9formin is essential in multiple processes that rely on actin
polymerization, such as blebbing [76] and actin nucleation
in the formation of cellular protrusions [77]; it also localizes
to stress fibres and filopodia [78]. MiR-130b-3p is also pre-
dicted to target CALM2, the calcium-binding protein
calmodulin (TargetScan ¼ 0.99, mirSVR ¼ 0.85, miRmap ¼
0.83). Complexes of calmodulin and Ca2þ bind to the actin-
binding domain of filamin A, an actin cross-linking protein,
dissociating filamin A from F-actin, thereby dissolving gels
of filamin A and F-actin [79]. The Rho GTPase-activating pro-
teins 1 (ARHGAP1) and 12 (ARHGAP12) are also predicted
targets of miR-130b-3p (ARHGAP1: TargetScan ¼ 0.94,
mirSVR ¼ 0.76, miRmap ¼ 0.90; ARHGAP12: TargetScan ¼
0.97, mirSVR ¼ 0.79, miRmap ¼ 0.95). Rho GTPase-activating
proteins (GAPs) stimulate Rho GTPase activity and promote
the conversion of active GTP-bound proteins to the inactive
GDP-bound state. In the activated state, Rho GTPases regu-
late F-actin assembly and enhance stress fibre formation
[80,81].3.5. Expression of key mechanoregulating genes is
altered by tumour-suppressor miRs
To experimentally confirm the altered expression of select
candidate targets following miR overexpression, we measure
transcript levels at 72 h post-transfection using real-time
polymerase chain reaction (qRT-PCR). We observe a signifi-
cant increase in ACTA2 (smooth muscle a-actin; two- to
sixfold) following treatment with miR-508-3p, miR-508-5p
and miR-130b-3p in HEYA8 cells (p, 0.01), but there is
no observable change following miR-509-3p overexpression
( p. 0.05). Overexpression of miR-130b-3p also reduces inva-
sion and shows an approximate twofold increase of ACTA2
in HEYA8 cells ( p, 0.01). While miR-508-5p also results in
a similar approximately twofold higher expression of
ACTA2 in HEYA8 cells ( p, 0.01) and a small increase in
transit time and retention ( p, 0.01), we observe no signifi-
cant effect on invasion ( p ¼ 0.4). For OVCAR8 cells, only
miR-130b-3p results in a significant change in ACTA2 levels
( p, 0.001); in contrast to HEYA8 cells, there is a decrease
in ACTA2 levels in OVCAR8 cells ( p, 0.001). Smooth
muscle a-actin associates predominantly with stress fibres
or microfilament bundles [82], and its expression correlates
with impaired motility in fibroblasts [83]. However, increased
ACTA2 levels are also associated with invasion in breast and
lung cancer [84,85]. The role of b-actin isoforms, which are
encoded by ACTB, in cytoskeletal organization and cell
migration is less well understood; b-actin is observed to
accumulate in cellular protrusions involved in motility [86],
while other studies report that b-actin is predominantly
found in stress fibres and at cell–cell adhesions [87]. ACTB
levels are not significantly altered in HEYA8 cells, but we
observe a significant decrease with overexpression of miR-
508-3p ( p, 0.01), miR-509-3p ( p, 0.001) and miR-509-5p
(p, 0.05) in OVCAR8 cells.
In addition to actin, we identify VIM and YAP1 as pre-
dicted miR targets and regulators of cell mechanical
properties and mechanotransduction. With overexpression
of miR-509-5p, we observe decreased vimentin expression
in both HEYA8 ( p ¼ 0.07) and OVCAR8 cells ( p, 0.001);
these observations are consistent with our target predictions
(VIM: TargetScan ¼ 0.97, mirSVR ¼ 1.00, miRmap ¼ 0.95;figure 5). We also observe changes in vimentin levels with
overexpression of other tumour-suppressor miRs. For
example, in HEYA8 cells we observe an approximate twofold
( p ¼ 0.003) increase in transcripts encoding for vimentin with
miR-508-3p; by contrast, OVCAR8 cells exhibit a less than
twofold decrease in vimentin with miR-508-3p ( p ¼ 0.04),
miR-509-3p ( p ¼ 0.003) and miR-130b-3p ( p ¼ 0.03).
Increased expression of vimentin is a marker for EMT,
which is associated with disease progression [64]; however,
the role of vimentin in cancer cell mechanical properties is
not fully understood [66,88]. As a cytoskeletal intermediate
filament protein, vimentin can contribute to cell stiffness
[65–67] and may enable cells to resist large deformations:
in vitro vimentin networks stiffen when deformed by large
stresses that can rupture actin networks [89]. Vimentin also
binds to plectin which mediates interactions of intermediate
filaments with actin and microtubules [90–92] (figure 5b).
YAP1 is a predicted target of miR-509-3p (TargetScan ¼
0.96, mirSVR ¼ 0.95, miRmap ¼ 0.97), and a transcriptional
co-activator and oncogene that is implicated in sensing mech-
anical cues and intracellular tension [93,94]; Yap1 localization
is sensitive to cell shape and polarity [93,95–97]. With
miR-509-3p overexpression, we observe a significant approxi-
mately fivefold downregulation of YAP1 in both HEYA8
and OVCAR8 cells ( p, 0.001) (figure 6). We previously
established YAP1 to be a direct downstream target of
miR-509-3p [3]. There is also an approximate twofold down-
regulation of YAP1 with miR-508-3p treatment in OVCAR8
cells ( p ¼ 0.003) but no significant change in HEYA8 cells.
Since Yap1 is implicated in sensing cytoskeletal tension
[93,94], we speculate that this protein could influence inva-
sive behaviour by dynamically regulating cell deformability
and traction forces as a cell migrates through narrow gaps.
However, the precise role of YAP1 in regulating the
invasive potential and deformability of single cells remains
to be clarified.3.6. Understanding the origins of altered deformability
and invasive behaviour
To further dissect the origins of the increased retention and
transit times that we observe with transfection of tumour-
suppressor miRs, we identify genes associated with
regulation of the cytoskeleton, which is a key regulator of
cell mechanotype [20,98]. The network shown in figure 5a
focuses on miRNA–mRNA and protein–protein interactions;
complementing this, the relevant molecular complexes and
structures that can determine cell physical properties are
illustrated in the schematic shown in figure 5b. Many of the
predicted and validated targets converge on regulation of
the actin cytoskeleton. Actin is a major cytoskeletal protein
that has three main isoforms in mammalian cells: a-actins
are a major component of the contractile apparatus, while b
and g-actins primarily regulate cell motility. These actin iso-
forms exist as monomers (G-actin), which can polymerize
to form filaments (F-actin) that play a key role in the morpho-
logical changes and physical forces generated during
migration [99,100]. The role of actin in regulating single-cell
mechanical properties is well established [20,31,44]. Here,
we experimentally confirm the predicted changes in actin
levels in the HEYA8 cells (figure 5a), which show a more
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10pronounced increase in monomeric actin levels than in the
OVCAR8 cells with miR overexpression.
To quantify levels and organization of F-actin in popu-
lations of miR-treated cells, we investigate cells that are
adhered to a collagen-coated substrate and labelled with
phalloidin; cells also adhere to collagen during invasion
(figure 2) [12]. We find that HEYA8 cells with elevated
levels of miR-508-3p, miR-509-3p and miR-130b-3p show a
two- to threefold increase in F-actin levels ( p, 0.05), whereas
cells with elevated levels of miR-508-5p and miR-509-5p
show a slight, albeit not statistically significant, increase in
F-actin ( p ¼ 0.83 and 0.84, respectively; figure 7c).
While knowledge of actin structure in adhered cells is rel-
evant for invasion, investigating F-actin in suspended cells is
relevant to our deformability assays, which measure cells in
suspension. Knowledge of subcellular architecture for sus-
pended cells may also be relevant because cells transit and
deform through vasculature during metastasis [101]. We
next use imaging flow cytometry to image single cells in sus-
pension, after being fixed and stained with phalloidin.
Representative images are shown in figure 7b. Compared to
the mock and SCR controls, cells overexpressing tumour-
suppressor miRs have increased F-actin levels (figure 7b,d ).
We observe the largest increase in F-actin levels for cells
that overexpress miR-508-3p, which exhibit approximately
eightfold higher levels of relative fluorescence intensity com-
pared to the mock and SCR controls (p ¼ 0.003; figure 7d ).
Cells overexpressing other tumour-suppressor miRs (miR-
508-5p, miR-509-3p, miR-509-5p and miR-130b-3p) show
approximately two- to fourfold higher levels of F-actin
relative to the controls ( p. 0.2). These increased levels of
F-actin are consistent with the longer transit times for cells
overexpressing tumour-suppressor miRs (R¼ 0.92, p ¼ 0.003)
and reflect how cytoskeletal organization determines transit
time and cell deformability.
We also investigate levels of F-actin in the cortical region,
as these are critical for the deformability of cells in suspension
[102,103]. Interestingly, our results show that cells with elev-
ated levels of miR-508-3p, miR-509-3p or miR-130b-3p, which
are less deformable, have lower levels of cortical-to-internal
F-actin than the mock and SCR cells (p, 0.001; electronic
supplementary material, figure S6). While lower levels of cor-
tical F-actin are typically associated with a more deformable
cortical region, as measured by methods that inducenanometre to submicrometre deformations [104], our PMF
and transit time measurements probe cells as they transit
through pores that are roughly half their size. The relatively
large deformations in our mechanotyping methods may
explain why levels of cortical-to-internal F-actin do not corre-
late with our deformability results; these observations are in
agreement with our previous report that the ratio of corti-
cal-to-internal F-actin cannot predict retention of ovarian
cancer cells during EMT [27].
Across the miR panel, we observe a similar trend in over-
all F-actin levels between cells in an adhered versus
suspended state, with smaller fold changes in F-actin levels
in adhered cells (figure 7). For example, for cells overexpres-
sing miR-508-3p, there is an eightfold increase in F-actin in
suspended cells (p ¼ 0.003), and only a threefold increase in
adhered cells (p, 0.001). The difference in phalloidin inten-
sity between cells in suspended versus adhered states is
consistent with how we image them: for flow cytometry ima-
ging, we capture light that is emitted from the entire cell
volume, whereas for confocal microscopy, we measure fluor-
escence signal from a single confocal slice. Taken together,
our imaging data for both adhered and suspended cells are
generally consistent with our qRT-PCR analyses, which
show a significant increase in ACTA2 (1.5 to 6-fold) with
overexpression of miR-508-3p, miR-508-5p, miR-509-5p and
miR-130b-3p.
As changes in the actin cytoskeleton can induce changes
in cell volume [105,106], and larger cells exhibit reduced
invasion [16,107], we also investigate cell size. To determine
differences in cell volume with miR overexpression, we ana-
lyse our flow cytometry imaging data; the size of cells in a
suspended state can be measured independently from the
effects of cell spreading that occur when cells are adhered
to a substrate [108,109]. We observe that cells with elevated
levels of tumour-suppressor miRs are on average 5–20%
larger than the parental cells and negative control-treated
cells: the median diameter of cells treated with tumour-sup-
pressor miRs range from 23 to 25 mm, while the SCR
control cells have a median diameter of 22 mm (electronic
supplementary material, table S1a and figure S5a). By stain-
ing cells with DRAQ5, we also obtain measurements of
nuclear size. We observe that the median diameters of
nuclei in miR-treated cells range from approximately 11 to
13 mm; this is approximately 10–26% larger than the nuclei
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11of the SCR control cells, which have a median diameter
of 10 mm ( p, 0.001; electronic supplementary material,
table S1b and figure S5b). An increase in cell and nuclear
size could contribute to increased transit time and retention;
however, cell and nuclear size do not exhibit signifi-
cant correlations with either transit time (cell size: R¼ 0.61,
p ¼ 0.14; nuclear size: R¼ 0.36, p ¼ 0.42) or retention (cell
size: R¼ 0.82, p ¼ 0.09; nuclear size: R¼ 0.66, p ¼ 0.23;
figure 8), suggesting that these deformability measurements
are not dominated by cell or nuclear size.
3.7. Determining correlations between cell physical
properties and invasive behaviour
To summarize the major contributions of cell physical
properties to invasive behaviour across the panel of
tumour-suppressor miRs, we determine the strength and
significance of correlations between invasion and cell size,
nuclear size, deformability (retention and transit time) and
F-actin levels (figure 8).
3.7.1. Cell invasion is negatively correlated with cell
and nuclear size
We find that across the panel of tumour-suppressor miRs,
cell size negatively correlates with invasion efficiency
(R ¼ 20.85, p, 0.05); these results are consistent with pre-
vious observations in fibroblast (HT-1080), lung (A125) and
breast cancer cells (MDA-MB-231) [16,107]. The nucleus is
typically the largest and stiffest organelle, occupying asubstantial volume of the cytoplasm and rate-limiting the
transit of cells through micrometre-scale pores [110–112];
nuclear size is also associated with how effectively cells
invade through collagen gels [16]. We observe a moderate
negative correlation between invasion and nuclear size
(R ¼ 20.83, p ¼ 0.02), reflecting how overexpression of
some miRs results in increased nuclear size as well as
reduced invasion, while overexpression of other miRs results
in larger nuclei but no significant change in invasion effi-
ciency. Thus, while we observe correlations between
invasive potential and cell/nuclear size, this feature alone
cannot predict how an individual miR will impact cell inva-
sive potential. Given recent observations of nuclear rupture
and repair during the migration of cells through confined
geometries [113], it remains to be determined how nuclear
size may impact disease progression in vivo.
3.7.2. Invasive behaviour of cells is weakly correlated
with deformability
To determine the deformability of populations of single cells
treated with a panel of miRs, we perform transit time
measurements. We also obtain complementary data using
PMF, which provides a bulk measure of the deformability
of a cell suspension. Considering the panel of miRs, we
observe a weak correlation between invasive behaviour and
retention (R ¼ 20.51, p ¼ 0.38) as well as transit time
(R ¼ 20.43, p ¼ 0.33), reflecting that less deformable cells
tend to be less invasive. This weak correlation reflects the
marked differences in the extent to which tumour-suppressor
miRs impact cell deformability and invasive behaviour. We
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Figure 8. Correlations between invasion, cell physical properties and F-actin
levels across the panel of tumour-suppressor miRs. Pearson correlation coeffi-
cient (R-value) between nuclear size, cell size, F-actin levels in suspended (S)
and adhered (A) cells, retention, transit time and invasion of cells with
elevated miR expression. *p , 0.05, **p , 0.01 indicate statistically signifi-
cant correlations.
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12find a statistically significant reduction in both cell
deformability and invasive potential for miR-508-3p and
miR-509-3p; these observations are consistent with previous
results showing that less deformable ovarian and breast
cancer cells have decreased invasion efficiency [16,23,24].
However, for other miRs there is little correspondence
between deformability and invasion. For example, cells over-
expressing miR-508-5p show increased retention but no
significant change in their invasive behaviour; cells with elev-
ated levels of miR-130b-3p are significantly less invasive but
only moderately less deformable. We note that invasion is an
active process during which the cell adheres to a substrate
and remodels its cytoskeleton on timescales of minutes
to hours, while our deformability measurements probe the
passive deformability of cells in suspension on timescales of
milliseconds to seconds [114].3.7.3. F-actin levels for adhered cells show the strongest
correlation with invasive potential
Our correlation analyses reveal a moderate negative corre-
lation between wound closure and F-actin levels in adhered
cells (R ¼ 20.89, p ¼ 0.008), suggesting that F-actin could
be an indicator of cell invasive potential. For example, in
HEYA8 cells miR-508-5p has no significant effect on cell
invasive potential ( p ¼ 0.37), nor on F-actin levels in adhered
cells (p ¼ 0.82); by contrast, miR-508-3p, miR-509-3p and
miR-130b-3p all induce a statistically significant decrease
in cell invasion ( p, 0.001) and increase in F-actin levels
( p, 0.015). While increased F-actin content is correlated
with increased invasion and cell motility in lymphoma cells
[115], other studies report that malignant cells exhibit a
marked decrease in F-actin compared with normal keratino-
cytes [116]. Additional factors can also regulate actin
structure and organization, including regulatory proteins,
which are involved in the potential interaction pathways
that we identify, such as DIAPH3 [117]; this formin promotes
the formation of actin-rich protrusions involved in cell
migration and invasion. For suspended cells, we find a nega-
tive albeit not statistically significant correlation between
F-actin levels and wound closure (R ¼ 20.44, p ¼ 0.33),indicating that the organization of cytoskeletal actin is more
tightly associated with invasive potential in adhered cells
than suspended cells.3.8. Potential mechanisms for how miRs alter cell
mechanotype and invasive behaviour
Here, we use predicted and validated targeting relationships
to associate the miRs with mRNA targets that encode struc-
tural and signalling proteins that regulate cell mechanical
properties and mechanosensing. We are thereby able to ident-
ify mechanisms by which altered levels of tumour-suppressor
miRs may alter regulation of cytoskeletal actin to make
cancer cells less deformable and less invasive. Changes in
cell mechanotype can occur due to regulation of F-actin struc-
ture and dynamics; this can be mediated by actin-associated
proteins, such as cross-linkers of actin filaments [118]. Remo-
delling of the actin cytoskeleton is required for numerous
processes in cancer invasion, including invadopodia for-
mation and motility [119,120]. Our work identifies several
targets whose potential role in ovarian cancer progression
warrants further investigation.
We focus first on dissecting the possible mechanism of the
phenotype induced by miR-508-3p overexpression, which
includes a strong decrease in invasion, increased transit
time and retention. Overexpression of miR-508-3p also results
in the largest increase in F-actin and ACTA2 transcript levels
in HEYA8 cells. A strong predicted target of miR-508-3p is
leupaxin (LPXN). Leupaxin interacts with integrins and
regulates the lifetime of adhesion sites [121]; since actin
polymerization is required for focal adhesion formation, we
speculate that reduced LPXN expression may alter actin
remodelling, and thereby affect cell deformability. Leupaxin
is also an interaction partner of the actin-binding protein
caldesmon, and thereby directly affects cytoskeletal struc-
ture and dynamics [54,55]. However, analysis of LPXN
expression using TCGA data through cBioPortal reveals
upregulation in only 4% of patients [122,123] (electronic sup-
plementary material, figure S7), and may therefore have
limited clinical impact. Similarly, miR-508-3p overexpression
in the p53-mutant OVCAR8 cells shows no significant effects
on invasion.
We find that miR-509-3p overexpression results in signifi-
cantly reduced invasion for both HEYA8 and OVCAR8, as
well as increased transit times and retention, which reflect a
trend to decreased deformability. Our results showing
reduced YAP1 levels in HEYA8 and OVCAR8 with miR-
509-3p overexpression are consistent with Yap1 being a vali-
dated target of miR-509-3p in ovarian cancer cells [3].
Downregulation of YAP1 by miR-509-3p could also alter
cell mechanical properties by regulation of ARHGAP18;
this Rho GTPase-activating protein (RhoGAP) regulates the
activity of RhoC [58] and RhoA [50]. Suppression of
ARHGAP18 could thus lead to accumulation of active Rho
and increased F-actin polymerization, which is consistent
with our imaging results for both adhered and suspended
cells following overexpression of miR-509-3p. Furthermore,
increased levels of miR-509-3p and decreased Yap1 levels
are associated with improved overall survival, as determined
by analysis of TCGA data [3].
In addition to ARHGAP18, our results reveal that
ARHGAP1 and ARHGAP12 are regulators of multiple
rsob.royalsocietypublishing.org
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13pathways. ARHGAP1 is another predicted target of miR-509-
3p; ARHGAP1 and ARHGAP12 are predicted to bind to miR-
130b-3p. Depletion of ARHGAPs could lead to increased
activation of Rho proteins and the formation of stress fibres
[50,124]; this is consistent with our results showing increased
F-actin and decreased cell deformability in HEYA8 cells
that overexpress miR-509-3p (figures 3, 4 and 7). Although
many RhoGAPs appear to have anti-tumourigenic effects
in other cancer types [125–127], ARHGAP1, ARHGAP12
and ARHGAP18 may have clinical relevance in ovarian
cancer: analysis of TCGA dataset through cBioPortal
[122,123] reveals that across 603 patient tumour samples,
there is upregulation or amplification of ARHGAP12 in
11% of patients, of ARHGAP1 in 5% of patients and of
ARHGAP18 in 4% of patients (electronic supplementary
material, figure S7). These findings warrant further investi-
gations of the role of these ARHGAPs in ovarian cancer cell
invasion and disease progression.
Rho proteins are also found in other pathways of our
interaction network. For example, RhoC is a predicted
target of miR-509-5p. Depletion of this RhoGTPase reduces
invasion in different cancer types from prostate to breast
cancer [128]. RhoC is also a validated target of miR-493 and
miR-138, which reduce the migration of cancer cells
[129,130]. RhoA is an effector of diaphanous-related formin-
3 or DIAPH3, which is implicated in multiple interaction
pathways (figure 5a). DIAPH3 is in the miR-509-3p/Yap1/
DIAPH3/actin axis and is also a predicted target of miR-
130b-3p, although overexpression of this miR results in
decreased invasion in HEYA8 cells only. While the role of
DIAPH3 in cell mechanical properties is poorly understood,
DIAPH3 may affect cell deformability through its interactions
with actin [78] and microtubules [131]: DIAPH3 remodels the
cytoskeleton by nucleating and elongating non-branched
actin filaments, thereby promoting F-actin formation [132].
Indeed, the downregulation of DIAPH3 in early to late
stage ovarian cancer cells is accompanied by disruption in
F-actin accumulation [133]. DIAPH3 also nucleates actin via
Cdc42 [75], and thereby contributes to remodelling of the
actin cytoskeleton, including the formation of protrusions
that are implicated in cell motility. For example, DIAPH3 is
enriched in the cellular protrusions of collagen-embedded
OVCA429 spheroids, and also contributes to the invasion of
ovarian cancer cells in two-dimensional cultures [134]. Con-
sistent with those findings, we find that overexpression of
miR-130b-3p, which is predicted to target DIAPH3, results
in reduced invasion of HEYA8 cells. DIAPH3 could also
impact cell invasive behaviour through the miR-509-3p/
Yap1/DIAPH3/actin axis. As expression of DIAPH3 corre-
lates with levels of active Yap1 [135], and overexpression of
miR-509-3p reduces Yap1 levels [3], we hypothesize that
miR-509-3p overexpression could also decrease DIAPH3
levels, which could destabilize actomyosin structures and
thereby cause cells to be less contractile and less invasive.
3.8.1. Differences between HEYA8 and OVCAR8
While we observe that miR-509-3p overexpression has a sig-
nificant effect on the invasion and deformability of both
HEYA8 and OVCAR8 cells, we also observe differences in
the behaviours of these two cell lines. For example, we find
that miR-508-3p, miR-509-3p and miR-130b-3p all signifi-
cantly reduce invasion of HEYA8 cells, but do not have asignificant effect on the invasive behaviour of OVCAR8
cells. The different trends that we observe between these
two cell lines probably reflect their distinct genetic back-
grounds: while HEYA8 is p53-wild-type, OVCAR8 is p53-
mutant. Mutation of the tumour-suppressor protein p53
may impact levels of key genes in our interaction network,
such as ACTA2 and NFKB1. Wild-type p53, but not mutant
p53, promotes increased activity of the smooth a-actin
promoter [82,136], which is consistent with the higher
endogenous levels of ACTA2 in HEYA8 cells versus
OVCAR8 that we observe by qRT-PCR (electronic sup-
plementary material, figure S8a) and also by analysis of
mRNA expression data from The Broad-Novartis Cancer
Cell Line Encyclopedia (CCLE) [137] (electronic supplemen-
tary material, figure S8b). We speculate that the higher
endogenous expression of ACTA2 in HEYA8 compared
with OVCAR8 cells could lead to the larger increase in
ACTA2 levels with miR-508-3p overexpression. Compared
to HEYA8 cells, OVCAR8 cells also have lower levels of
NFKB1 and higher levels of the Rho GTPase RHOB (elec-
tronic supplementary material, figure S8b); this is consistent
with the suppression of NF-kB by RhoB [138]. As NFKB1 is
a highly scoring predicted target of miR-508-3p, overexpres-
sion of this miR may have a more significant effect on the
invasion behaviour and physical properties of HEYA8
rather than OVCAR8 cells. We also observe that certain pre-
dicted miR targets are expressed at different levels in
HEYA8 and OVCAR8 cells. For example, a predicted target
of miR-130b-3p, ARHGAP12, has slightly lower levels in
OVCAR8 than HEYA8 cells (electronic supplementary
material, figure S8a); therefore, a reduction of ARHGAP12
levels by miR-130b-3p may result in more significant
reduction of invasion in HEYA8 cells. In addition to the
p53 mutation, OVCAR8 cells have a number of additional
mutations compared to HEYA8 cells, which could also
result in phenotypic differences between the two cell lines
[139]. Differences between HEYA8 and OVCAR8 with miR
overexpression may also be related to the 10 greater fold
increase in levels of miR-508-3p and miR-130b-3p in
HEYA8 than in OVCAR8 cells. Both miR-508-3p and miR-
130b-3p exhibit more significant effects on the invasion and
mechanotype of HEYA8 cells than of OVCAR8 cells. How-
ever, we find there are no significant correlations between
miR expression levels, invasive behaviour and physical phe-
notypes including deformability, F-actin levels and cell/
nuclear size ( p. 0.05); these findings indicate that altered
expression of specific miR targets and/or downstream effec-
tors may have a stronger effect than levels of miRs alone.
Further studies can provide deeper insight into the effects
of tumour-suppressor miRs on the behaviour of different
ovarian cancer cell types.4. Conclusion
MiRs play central roles in regulating gene expression and cel-
lular functions across a wide range of biological processes,
from embryogenesis to stem cell differentiation to cancer.
Here, we dissect the role of single-cell physical properties in
cell invasive behaviour following upregulation of tumour-
suppressor miRs in two human ovarian cancer cell lines.
We focus on a panel of five tumour-suppressor miRs that
are expressed at lower levels in later stages of human ovarian
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14cancer and are more abundant in patients with improved
survival [3,33,140,141]. The mechanome targets of these
miRs that we have identified may be implicated in ovarian
cancer progression and warrant further investigation.
Our results also deepen our understanding of how cell/
nuclear size, deformability and architecture of the actin cyto-
skeleton could have functional consequences in cancer
invasion. For adhered cells, we find that cell invasive poten-
tial is strongly correlated with cellular and nuclear size, as
well as F-actin levels. With overexpression of certain miRs,
such as miR-508-3p in HEYA8 cells, our results show that
cells become less deformable and also less invasive. Thus,
our findings also suggest that measurements of cell physical
properties could complement existing methods to identify
potential therapeutics.
Investigating other physical factors that are implicated in
invasion may provide additional insights. Invasion is a com-
plex and dynamic process in which cells remodel the ECM by
proteolytic degradation and by exerting traction forces on
surrounding ECM fibres. Differences in the adhesive proper-
ties of cells could also contribute to the differences in cell
invasion that we observe in cells overexpressing tumour-sup-
pressor miRs. In addition to changes in cell physical
properties, the ECM also regulates invasion through its
mechanical properties and density of cell adhesion binding
sites [17,142–144]. Complementary analyses of cell and
ECM physical parameters and/or combinations of parameters
could thus provide stronger predictive power for diagnosis and
treatment response. Ultimately, knowledge of physicalproperties of tumour cells and their microenvironment could
lead to new strategies to better target invasive cancer cells
and to reduce metastatic spread.
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